Abstract | OBJECTIVES: BACKGROUND: METHODS: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n = 9) or losartan 50 mg twice a day (n = 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. RESULTS: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]: +5% [-4% to +21%] with placebo vs. -5% [-11% to -0.9%] with losartan; p = 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs. -23% ± 45% with losartan; p = 0.03). CONCLUSIONS:
|
Authors | Yuichi J Shimada, Jonathan J Passeri, Aaron L Baggish, Caitlin O'Callaghan, Patricia A Lowry, Gia Yannekis, Suhny Abbara, Brian B Ghoshhajra, Richard D Rothman, Carolyn Y Ho, James L Januzzi, Christine E Seidman, Michael A Fifer |
Journal | JACC. Heart failure
(JACC Heart Fail)
Vol. 1
Issue 6
Pg. 480-7
(Dec 2013)
ISSN: 2213-1787 [Electronic] United States |
PMID | 24621999
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Losartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(administration & dosage)
- Cardiomyopathy, Hypertrophic
(complications)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Fibrosis
(drug therapy)
- Humans
- Hypertrophy, Left Ventricular
(complications, drug therapy)
- Losartan
(administration & dosage)
- Magnetic Resonance Angiography
- Male
- Middle Aged
- Myocardium
(pathology)
- Pilot Projects
- Prospective Studies
|